$23.54
+0.41 (+1.77%)
Open$24.10
Previous Close$23.13
Day High$24.76
Day Low$23.18
52W High$29.75
52W Low$11.51
Volume—
Avg Volume398.8K
Market Cap1.66B
P/E Ratio—
EPS$-1.37
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
-24.1% upside
Current
$23.54
$23.54
Target
$17.86
$17.86
$12.55
$17.86 avg
$20.90
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 106.06M | 166.83M | 182.20M |
| Net Income | -81,196,804 | -114,955,361 | 28.41M |
| Profit Margin | -76.6% | -72.7% | 15.6% |
| EBITDA | -88,954,990 | -132,935,725 | 52.86M |
| Free Cash Flow | — | — | 21.80M |
| Rev Growth | -36.4% | -36.4% | +8.1% |
| Debt/Equity | — | — | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |